Certara initiated with a Buy at TD Cowen

TD Cowen analyst Brendan Smith initiated coverage of Certara (CERT) with a Buy rating and $16 price target The “breadth and evolution” of the company’s Model-informed Drug Development platform are underappreciated and position Certara for above-market growth as biosimulation becomes standard operating procedure, the analyst tells investors in a research note. The firm says the company’s ongoing review of low-margin Regulatory Science Services business should address a key overhang and support a shift to margin expansion, the analyst tells investors in a research note.